Form 4: Niagen Bioscience CEO Acquires Shares

Robert N. Fried, CEO of Niagen Bioscience, Inc., acquired 20,000 shares of common stock through the exercise of stock options.

Summary

• Robert N. Fried, Chief Executive Officer and Director of Niagen Bioscience, Inc. (NAGE), acquired 20,000 shares of common stock on April 24, 2026.
• The acquisition was made by exercising stock options at a price of $2.61 per share.
• These options were exercised in advance of their expiration date of November 15, 2026.
• Fried has not sold any of the shares received upon exercise.
• Following this transaction, Fried directly beneficially owns 1,058,981 shares of common stock.
• Additional shares are held indirectly through trusts, including the Fried-Travis Revocable Trust and two irrevocable trusts for his sons, Jeremy W. Fried and Benjamin A. Fried.
• Fried also disclaims beneficial ownership of securities held in the irrevocable trusts for his sons.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing due to the CEO's acquisition of shares, signaling confidence, although it's a standard insider transaction without new financial data.

Positives

• CEO Robert N. Fried demonstrated confidence in the company by exercising stock options and acquiring additional shares.
• The acquisition of 20,000 shares at $2.61 per share indicates a belief in the current valuation or future prospects of Niagen Bioscience.
• The CEO has not sold any shares post-exercise, suggesting a long-term holding strategy.

Negatives

• The filing does not contain any negative financial results or operational setbacks.
• No indication of any negative market reaction or analyst downgrades is present in this specific filing.

Risks

• The filing does not explicitly mention any new or evolving risks.
• The exercise of options prior to expiration could be interpreted as a need for liquidity, though this is not stated.

Future Outlook

The filing does not contain specific forward-looking statements or guidance. However, the CEO's acquisition of shares suggests a positive outlook on the company's future performance.

Management Comments

• The Reporting Person exercised the stock options reported on this Form 4 in advance of their expiration on November 15, 2026, paying the exercise price with cash, and has not sold any of the shares received upon exercise.
• The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Industry Context

StockSavvy.ai notes that insider stock option exercises, particularly by senior management like CEOs, are often viewed as a signal of confidence in the company's intrinsic value and future growth prospects. This action by Robert N. Fried aligns with typical insider behavior when management believes the stock is undervalued or poised for appreciation.

Related Party Transactions

• Robert N. Fried is the CEO and Director of Niagen Bioscience, Inc.
• Shares are held indirectly by the Fried-Travis Revocable Trust U/A Dated 06/02/1999.
• Shares are held indirectly by US Trust Co. of Delaware Trustee of The Jeremy W Fried 2020 Irrevocable Trust dated 02/26/2020.
• Shares are held indirectly by US Trust Co. of Delaware Trustee of The Benjamin A Fried 2020 Irrevocable Trust dated 02/26/2020.
• 6,745 shares of Common Stock are held by Jeremy Fried (son of Robert Fried).
• 6,001 shares of Common Stock are held by Benjamin Fried (son of Robert Fried).

Stakeholder Impact

• Shareholders may view the CEO's acquisition positively, interpreting it as a sign of confidence in the company's future.
• Employees may be encouraged by leadership's commitment to the company's success.
• Creditors and suppliers are not directly impacted by this insider transaction.

Next Steps

• Monitor future filings for any subsequent transactions by Robert N. Fried or other insiders.
• Observe the company's stock performance following this insider acquisition.

Key Dates

Recommendation

This Form 4 filing indicates an insider acquisition of shares via option exercise by the CEO, which is generally a positive signal. However, it does not provide new financial performance data or strategic updates that would warrant a stronger recommendation. Therefore, a 'hold' recommendation is appropriate, suggesting investors maintain their current positions while awaiting further company developments.

Keywords

Niagen Bioscience, NAGE, Form 4, Stock Options, Insider Transaction, Robert N. Fried, Beneficial Ownership, Securities Acquisition, CEO, Director